These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 34000372

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW, Trivedi T, Montgomery M, Petrovic DF, Yamaji R, Riley L.
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [Abstract] [Full Text] [Related]

  • 7. Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    Bayart J, Drouet J, Peycelon M, Mariani P, Le Roux E, Husain M, Agar J, Bonacorsi S, Caseris M.
    J Antimicrob Chemother; 2024 Apr 02; 79(4):918-922. PubMed ID: 38412330
    [Abstract] [Full Text] [Related]

  • 8. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB, Lee SC, Lee SY, Jeong DC, Kang JH.
    BMC Infect Dis; 2015 Oct 13; 15():414. PubMed ID: 26464143
    [Abstract] [Full Text] [Related]

  • 9. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D, Lusa L, Klevišar MN, Terzić S, Pirš M, Premru MM, Strle F.
    Int J Antimicrob Agents; 2017 Oct 13; 50(4):564-571. PubMed ID: 28711676
    [Abstract] [Full Text] [Related]

  • 10. Urinary Tract Infections in Kidney Transplant Patients Due to Escherichia coli and Klebsiella pneumoniae-Producing Extended-Spectrum β-Lactamases: Risk Factors and Molecular Epidemiology.
    Espinar MJ, Miranda IM, Costa-de-Oliveira S, Rocha R, Rodrigues AG, Pina-Vaz C.
    PLoS One; 2015 Oct 13; 10(8):e0134737. PubMed ID: 26237422
    [Abstract] [Full Text] [Related]

  • 11. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France.
    Duployez C, Loïez C, Cattoen C, Wallet F, Vachée A.
    Med Mal Infect; 2019 Feb 13; 49(1):47-53. PubMed ID: 30396720
    [Abstract] [Full Text] [Related]

  • 12. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
    Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G.
    BMC Infect Dis; 2016 Aug 18; 16(1):427. PubMed ID: 27538488
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
    Aslan AT, Akova M.
    Expert Rev Anti Infect Ther; 2019 Dec 18; 17(12):969-981. PubMed ID: 31722185
    [Abstract] [Full Text] [Related]

  • 15. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Doi A, Shimada T, Harada S, Iwata K, Kamiya T.
    Int J Infect Dis; 2013 Mar 18; 17(3):e159-63. PubMed ID: 23140947
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ESBL-producing enterobacteriaceae-related urinary tract infections in kidney transplant recipients: incidence and risk factors for recurrence.
    Pilmis B, Scemla A, Join-Lambert O, Mamzer MF, Lortholary O, Legendre C, Zahar JR.
    Infect Dis (Lond); 2015 Mar 18; 47(10):714-8. PubMed ID: 26024285
    [Abstract] [Full Text] [Related]

  • 18. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
    Deemer K, Grey J, Fronczek C, Marr K.
    Am J Health Syst Pharm; 2020 Nov 16; 77(Supplement_4):S105-S110. PubMed ID: 32840305
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
    Zhang H, Liang B, Wang J, Cai Y.
    Int J Antimicrob Agents; 2021 Oct 16; 58(4):106410. PubMed ID: 34339776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.